跳至主要内容
临床试验/NCT02326922
NCT02326922已完成1 期

The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding

Ain Shams Maternity Hospital1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2014年6月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
61
试验地点
1
主要终点
Amount of menstrual blood loss (MBL) in women with menorrhagia by means of pictorial bleeding assesment chart

研究概览

简要总结

Research hypothesis: Release of levonorgestrel from Metraplant-E levonorgestrel releasing intrauterine contraceptive device is inadequate to be used as a medical line of treatment of dysfunctional uterine bleeding.

The investigators aim to evaluate the therapeutic effect of the intrauterine system (Metraplant-E) in the treatment of dysfunctional uterine bleeding.

详细描述

Primary outcome : The investigators aim to evaluate the short term release of levonorgestrel from the Metraplant-E levonorgestrel releasing intrauterine contraceptive devices (IUCDs). This is in a trial to determine to what extent the intrauterine release of levonorgestrel would reduce MBL in women with menorrhagia and if the treatment would increase the body iron stores and the degree of patient satisfaction and acceptability of treatment for the patients with dysfunctional uterine bleeding. This will be conducted through a questionnaire offered to the women participating in this study which is designed on Likert scale.

Secondary outcome:

  1. Endometrial biopsy prior to and 6 months after the insertion of the intrauterine system (Metraplant-E).

  2. Haemoglobin level measurement in gm/dl and serum ferritin level on same occasions as when endometrial biopsy is done.

  3. The amount of monthly menstrual blood loss after the insertion the Metraplant-E levonorgestrel releasing intrauterine contraceptive devices using the following scores: bleeding index,total bleeding score and Pictorial blood loss assessment chart (PBAC).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women seeking contraception.
  • Women with history of menorrhagia.
  • Pre and perimenopausal women who are married or previously married.
  • Failure of other medical treatment to control menorrhagia such as hemostatics.
  • Women who did not tolerate copper IUD due to increased amount of menstrual blood loss which could lead to anemia.

排除标准

  • History of ectopic pregnancy .
  • Pregnancy or suspicion of pregnancy.
  • Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity.
  • Acute pelvic inflammatory disease
  • Postpartum endometritis or infected abortion in the past 3 months.
  • Known or suspected uterine or cervical neoplasia or unresolved, abnormal Pap smear.
  • Genital bleeding of unknown etiology.
  • Untreated acute cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections, until infection is controlled.
  • Acute liver disease or liver tumor (benign or malignant).
  • Conditions associated with increased susceptibility to infections with microorganisms. Such conditions include, but are not limited to, leukemia, acquired immune deficiency syndrome (AIDS), and I.V. drug abuse.
  • A previously inserted IUD that has not been removed.
  • Hypersensitivity to any component of this product.
  • Women taking anticoagulants
  • Women with coagulopathies due to thrombocytopenia or platelets dysfunction.
  • Known or suspected carcinoma of the breast.

结局指标

主要结局

Amount of menstrual blood loss (MBL) in women with menorrhagia by means of pictorial bleeding assesment chart

时间窗: 6 months

This is in a trial to determine to what extent the intrauterine release of levonorgestrel would reduce menstrual blood loss (MBL) in women with menorrhagia and if the treatment would increase the body iron stores and the degree of patient satisfaction and acceptability of treatment for the patients with dysfunctional uterine bleeding. This will be conducted through a questionnaire offered to the women participating in this study which is designed on Likert scale.

次要结局

  • Hemoglobin level in blood prior to the device insertion and 6 months afterwards(6 months)
  • Histological changes in Endometrial biopsy prior to and 6 months after the insertion of the intrauterine system (Metraplant-E)(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alshaimaa Ahmad Aboulfetouh Mahmoud

Obgyn resident

Ain Shams Maternity Hospital

研究点 (1)

Loading locations...

相似试验